Services
Data processing and predictive models
Advanced imaging data processing
Laboratory phenotype analysis
Educational
Single OMIC e multiOmics
Service Title
Participants
The INNOVA – Hub Life Science – Advanced Diagnostics (HLS-DA) project, as designated by all the spokes, is coordinated and directed by the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
The 43 institutions included in the HUB, comprising research hospitals (“IRCCS”), general hospitals, universities, and research centers, are as follows:
1
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
MAGGIORE
2
IRCCS Istituto Clinico Humanitas – Humanitas Mirasole spa
Humanitas
3
IRCCS Ospedale Policlinico San Martino
HSM
4
Fondazione I.R.C.C.S. Policlinico San Matteo
OSM-PV
5
IRCCS IFO Istituti Fisioterapici Ospitalieri
IRE-IFO
6
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gemelli
7
IRCCS Istituto Neurologico Mediterraneo Neuromed
NEUROMED
8
Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”
Pascale
9
Centro Cardiologico Monzino IRCCS
CCM
10
Fondazione IRCCS Istituto Neurologico Carlo Besta
Besta
11
IRCCS Fondazione Mondino
Mondino
12
Politecnico di Milano
POLIMI
13
Istituto Auxologico Italiano
Auxo
14
Centro di Riferimento Oncologico di Aviano, IRCCS
CRO Aviano
15
Università degli Studi di Parma
UNIPR
16
Università degli Studi di Verona
UniVer
17
Fondazione Santa Lucia
FSL
18
Università Degli Studi Di Roma Tor Vergata
UniTorVergata
19
IRCCS Istituto Oncologico ‘Giovanni Paolo II’
ITGPII
20
IRCCS ISMETT
ISMETT
21
IRCCS CENTRO NEUROLESI BONINO PULEJO
CNBP
22
Università degli studi di Palermo
UNIPA
23
Università degli Studi di Bari Aldo Moro
UNIBA
24
Centro Regionale Information Communication Technology scrl
CERICT
25
IRCCS Centro San Giovanni di Dio Fatebenefratelli
IRCCSFBF
26
IRCCS Ospedale Sacro Cuore Don Calabria
IRCCSSDC
27
IRCCS MultiMedica – MultiMedica SpA
IRCCSMM
28
IRCCS E. Medea dell’Associazione La Nostra Famiglia
E.Medea
29
Fondazione Don Carlo Gnocchi – Onlus
DCG
30
Azienda Socio Sanitaria Territoriale dei Sette Laghi – Polo Universitario
ASST Sette Laghi
31
AOU Città della Salute e della Scienza di Torino
AOU TO
32
Azienda Ospedaliera Universitaria Integrata Verona
AOUI Verona
33
Università degli Studi di Torino
UNITO
34
Università degli Studi di Trento
UNITRE
35
Fondazione Stella Maris
Stella Maris
36
IRCCS San Raffaele – Roma
San Raffaele
37
Azienda ospedaliero-universitaria Senese
AOUS
38
Università degli Studi di Firenze
UNIFI
39
Ispro Istituto per lo Studio, la prevenzione e la rete oncologica
ISPRO
40
Fondazione Toscana Gabriele Monasterio
FTGM
41
Ente Ospedaliero Specializzato in Gastroenterologia “Saverio de Bellis” – IRCCS
IRCCS SdB
42
IRCCS SYNLAB SDN SPA
SYNLAB SDN
43
Azienda di Rilievo Nazionale e di Alta Specializzazione – Civico Di Cristina Benfratelli (ARNAS-Civico)
ARNAS-Civico
Hub & Spoke
The HUB comprises 43 institutions, including research hospitals (“IRCCS”), general hospitals, universities, and research centers, 8 of which function as first-level spokes, 16 as level 2A spokes, and 19 as level 2B spokes.
This heterogeneous group of Italian clinicians and scientists, affiliated with both public and private healthcare and academic institutions, with varying levels of expertise and technological infrastructure in different areas of human diseases, will work together for the production of new diagnostic approaches that integrate clinical, phenotypic, and omics data into the clinical decision-making process for well-selected patients. These patients can then benefit from targeted and innovative therapies.
The Metodology
The partners will periodically verify if the project’s approach is in line with available technologies, implementing sustainable strategic and economic choices. In this context, the collaboration of INNOVA with the R&D division of diagnostic companies and startups will be strategic for the validation of development and the commercial enhancement of diagnostic devices.
The network will utilize innovative methodologies and strategies for the collection and analysis of clinical and laboratory data, organized in a step-wise structure:
- collection of clinical and laboratory data to perform accurate phenotypic characterization;
- creation of standardized methods for exchanging work protocols;
- development and facilitation of the availability of local and core service packages for biochemical and molecular laboratory biomarkers associated with the aforementioned non-communicable diseases;
- implementation of local and core facilities for high-resolution morphological imaging of organs, functional imaging of target tissues, and molecular imaging;
- integration of multiomic data (radiomics, cell-type-specific high-throughput genomics, epigenomics, transcriptomics, etc.);
- Integration, through artificial intelligence, of clinical, imaging, phenotypic, and omic data for the identification of specific diagnostic pathways for pathology and potential therapeutic response markers.
Work Package
A technological infrastructure and methods for specific organ microvascular dysfunction
Leader: Maggiore (SD: F. Blandini, PI: F. Peyvandi)
Co-leader: Gemelli (SD: G. Scambia, PI: M. Sanguinetti)
a NHS Service to enhance the informative content of diagnostic imaging
Leader: HSM (SD: A. Uccelli, PI: G. Sambuceti)
Co-leader: Humanitas (SD: A. Mantovani, PI: L. Politi)
A multidisciplinary platform to process innovative immunity and inflammatory biomarkers for precision medicine
Leader: Humanitas (SD: A. Mantovani, PI: C. Garlanda)
Co-leader: HSM (SD: A. Uccelli, PI: G. Filaci)
A high-resolution Liquid Biopsy-based national reference hub for next generation diagnostics leveraging
Leader: IRE/IFO (SD: G. Ciliberto, PI: G. Blandino)
Co-leader: Pascale (SD: A. Budillon, PI: N. Normanno)
Multimodal data harvesting and merging tools for the creation of reliable predictive models
Leader: Gemelli (SD: G. Scambia, PI: M. Sanguinetti)
Co-leader: OSM-PV (SD: V. Bellotti, PI: E. Arbustini)
Multiomics and radiomics pipe
Leader: OSM-PV (SD: V. Bellotti, PI: E. Arbustini)
Co-leader: Neuromed (SD: L. Frati, PI: G. Lembo)
A platform for multiomic profiling and predictive algorithms of resistance to target therapy and immunotherapy
Leader: Pascale (SD: A. Budillon, PI: N. Normanno)
Co-leader: IRE-IFO (SD: G. Ciliberto, PI: G. Blandino)
Platforms and diagnostic products for early diagnosis and prevention of degenerative diseases
Leader: Neuromed (SD: L. Frati, Scientific PI: N. D’Ascenzo)
Co-leader: Maggiore (SD: F. Blandini, Scientific PI: F. Peyvandi)
Leader: Maggiore (SD: F. Blandini, Scientific PI: F. Peyvandi)
The Mission
INNOVA will support the scientific community by interfacing with clinical and industrial entities in the Life Sciences field, through targeted actions that will drive translational research and innovation ecosystem for major human diseases (neurological, cardiovascular, inflammatory, metabolic, oncological), proposing widespread, accessible, and sustainable innovative diagnostic approaches throughout Italy.
The program will catalyze interactions with key stakeholders in the sector, including CROs, pharmaceutical companies, medical device companies, and software companies, which will contribute to the long-term sustainability of the program.
Our main objective is to make available a large number of phenotypic biomarkers, ‘omics,’ and imaging markers involved at multiple levels in the pathogenetic and pathophysiological aspects of the diseases targeted by the INNOVA program, developing an integrated and advanced diagnostic platform that will provide new tools for prevention, early diagnosis, drug development, and therapeutic monitoring according to the principles of personalized and precision medicine.
This process will unfold through an initial phase of biomarker validation and diagnostic pathways within the scope of non-communicable diseases, with particular attention to those with difficult diagnosis, poor therapeutic response, and unfavorable prognosis.
The multidisciplinary platform INNOVA will combine digital technologies and wet methods for the collection of high-quality data, providing researchers and the healthcare system with advanced diagnostic tools. The digitization and sharing of data will also enable the use of artificial intelligence for the standardization of specific pathways and consequently for the definition of guidelines and advanced diagnostic pathways in various pathologies. This platform, together with specific training and education services, will allow for the systematic expansion and organization of the scientific and technological capabilities of the affiliated Spokes, harmonizing the level of healthcare nationwide.
INNOVA will also have a significant impact on future diagnostic strategies and will improve personalized clinical decisions in specific pathologies across various disciplinary sectors.
Home-en
The Mission
The mission of INNOVA project is to create a multidisciplinary advanced diagnostic platform operating within the Italian system of health care and translational research. The platform will promote the development and dissemination of standardized advanced diagnostics in the fields of wet laboratory and bioimaging technologies throughout the country, with a Hub & Spoke architecture.
Hub & Spoke
The Hub & Spoke network will survey how the shift from standard diagnostic strategy to future multimodal strategies can improve outcomes and individualized clinical decisions. The network will benefit of the critical mass of the technological expertise provided by its members in order to draw up shared procedures leading to new tools, methods, and guidelines in the field of novel advanced diagnostics available to relevant national and international stakeholders.